## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.2% below STRENGTH zone (4.0-10.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($201.93)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2026 on February 5**
- Source: Cardinal Health | 20260106T114859 | Neutral | Relevance: 100%
- Cardinal Health (NYSE: CAH) plans to release its second-quarter financial results for fiscal year 2026 on February 5, before the New York Stock Exchange opens. The company will webcast a discussion of these results at 8:30 a.m. Eastern, accessible through its Investor Relations page. Presentation slides and a replay will be available for 12 months.

**2. Is Cardinal Health (CAH) Still Offering Value After A 71% One Year Share Price Surge**
- Source: Simply Wall Street | 20260106T050823 | Bullish | Relevance: 100%
- Cardinal Health (CAH) has seen a significant share price surge of 71.4% over the last year. A Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 55.5% compared to its intrinsic value of around $461.54 per share. However, its P/E ratio of 30.6x is close to Simply Wall St's Fair Ratio of 30.8x, indicating it is fairly priced by this metric.

**3. Cardinal Health, Inc. $CAH Shares Purchased by Robeco Institutional Asset Management B.V.**
- Source: MarketBeat | 20260106T120359 | Bullish | Relevance: 100%
- Robeco Institutional Asset Management B.V. increased its stake in Cardinal Health, Inc. (NYSE:CAH) by 16.8% in Q3, now owning 936,747 shares valued at $147 million. Other institutional investors also adjusted their positions in the company. Cardinal Health reported strong Q3 earnings, surpassing analyst estimates, and declared a quarterly dividend of $0.5107.

**4. Is Cardinal Health (CAH) Still Offering Value After A 71% One Year Share Price Surge**
- Source: Simply Wall Street | 20260106T053058 | Bullish | Relevance: 100%
- Cardinal Health (CAH) has seen a 71% share price surge, leading investors to question its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 55.5%, estimating an intrinsic value of $461.54 per share compared to its current $205.45. However, its P/E ratio of 30.6x is above the industry average but aligns closely with Simply Wall St's Fair Ratio, indicating it is currently fairly priced by this metric.

**5. Cardinal Health (CAH) repositions for growth with specialty and services**
- Source: MSN | 20260104T230804 | Bullish | Relevance: 100%
- Cardinal Health is strategically repositioning itself by focusing on specialty pharmaceuticals and services. This move aims to leverage the growing market for complex therapies and enhance its service offerings, departing from its traditional distribution model to drive future growth and profitability. The company is investing in advanced logistics and data analytics to support this shift.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $49.5B |
| Beta | 0.65 |
| 52W Range | $119.11 - $214.93 |
| Short Interest | 2.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 18.8 |
| Current P/E | 21.2 |
| YoY Growth | 12.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 2.2% (minimal 5-day change). Below STRENGTH zone by 1.8pp (needs >4.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.17% (CS: 60) | Neutral |
| RSI_14 | 65.8 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.276x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $208.51
- **Stop Loss:** $201.93 (3.2% risk)
- **Target:** $215.09 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 200
- **Position Value:** $41,702.00
- **Portfolio %:** 41.70%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.6% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*